Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoff Schembri

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Clinical Endocrinology|May 10, 2018
Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomasMatti L Gild, Nikita Naik, Jeremy Hoang, et al.
Pancreas|July 10, 2024
Metabolic Tumor Volume on 18-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Marker of Survival in Patients With Locally Advanced or Metastatic Neuroendocrine Neoplasms Treated With 177Lutetium-DOTA-Octreotate Peptide Receptor Radionuclide TherapyMadhawa K De Silva, David L H Chan, Elizabeth J Bernard, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|September 24, 2018
FET PET in the evaluation of indeterminate brain lesions on MRI: Differentiating glioma from other non-neoplastic causes - A pilot studyDavid L Chan, Edward Hsiao, Geoff Schembri, et al.
The Lancet. Oncology|April 15, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The Lancet. Oncology|February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Clinical Endocrinology|May 10, 2018
Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomasMatti L Gild, Nikita Naik, Jeremy Hoang, et al.
Pancreas|July 10, 2024
Metabolic Tumor Volume on 18-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Marker of Survival in Patients With Locally Advanced or Metastatic Neuroendocrine Neoplasms Treated With 177Lutetium-DOTA-Octreotate Peptide Receptor Radionuclide TherapyMadhawa K De Silva, David L H Chan, Elizabeth J Bernard, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|September 24, 2018
FET PET in the evaluation of indeterminate brain lesions on MRI: Differentiating glioma from other non-neoplastic causes - A pilot studyDavid L Chan, Edward Hsiao, Geoff Schembri, et al.
The Lancet. Oncology|April 15, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The Lancet. Oncology|February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
Pageof 2